OKYO Pharma Limited Ordinary Shares (OKYO)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach OKYO as a Graham-style exercise in separating a story from a balance sheet. The story is clear: a London-based ophthalmology company with five employees, developing urcosimod in Phase 2 for dry eye disease and neuropathic corneal pain, plus OK-201 for ocular pain. But the filed financial picture is not a business yet. Revenue growth is not available, and the FairStock P/E at the 2026-10-13 close of $1.44 is -5.99. The market capitalization is $83.4M, while FairStock-calculated P/B is 6.25, ROE is -263.78%, and ROCE is -43.10%. Those are not the marks of a durable franchise; they reflect a company burning capital while seeking clinical proof. The Piotroski F-Score of 1/9 and Altman Z-Score of -3.64, both FairStock calculations, point to weak financial health and distress risk. FairStock Score 20/100 and a Lynch category of none, because only zero years of filed results are available, reinforce that there is little operating history to underwrite. The 52-week range of $1.26-$3.20 and beta of -0.06 tell me the stock has been volatile in its own way, but volatility is not value. In my view, OKYO has no demonstrable moat today; any future moat depends on patents, trial data, and regulatory approval, none of which are in the figures. Growth trajectory is binary: positive Phase 2 results could transform prospects, but failure or delay would leave a cash-consuming shell. I would need much more evidence before calling this a bargain.

In plain English: OKYO Pharma is a small clinical-stage drug company working on eye treatments, including a lead therapy in mid-stage human testing for dry eye and nerve-related eye pain. The business looks weak today: it does not report revenue growth and is losing money, with very few employees and no filed track record to judge. At $1.44, the price does not look cheap against those numbers; it is a speculative bet on future trial results rather than on current profits or reported growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer